Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company's second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has completed Phase I clinical trial and is a workhorse chemotherapeutic drug used for various cancers. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instrumentation to hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through a combination of a direct sales force, third-party distributors, independent sales representatives, and licensees. In addition, the company markets and sells its proprietary enzymatic reagents under the Celase and Intravase brands. It has operations in the Americas, Japan, EMEA, and the Asia Pacific. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CYTX
CUSIP23283K10
Phone858-458-0900
Debt
Debt-to-Equity RatioN/A
Current Ratio0.42
Quick Ratio0.25
Price-To-Earnings
Trailing P/E Ratio-0.06
Forward P/E Ratio-0.47
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.69 million
Price / Sales1.15
Cash FlowN/A
Price / CashN/A
Book Value$2.25 per share
Price / Book0.18
Profitability
EPS (Most Recent Fiscal Year)($6.50)
Net Income$-22,680,000.00
Net Margins-380.64%
Return on Equity-202.09%
Return on Assets-64.08%
Miscellaneous
Employees37
Outstanding Shares7,710,000
Market Cap$3.26 million
Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions
What is Cytori Therapeutics' stock symbol?
Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."
When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?
Cytori Therapeutics's stock reverse split on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 10 shares after the split.
How were Cytori Therapeutics' earnings last quarter?
Cytori Therapeutics Inc (NASDAQ:CYTX) issued its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.09. The biotechnology company earned $1.56 million during the quarter, compared to analyst estimates of $2.50 million. Cytori Therapeutics had a negative return on equity of 202.09% and a negative net margin of 380.64%. View Cytori Therapeutics' Earnings History.
When is Cytori Therapeutics' next earnings date?
What price target have analysts set for CYTX?
4 brokers have issued 12 month price objectives for Cytori Therapeutics' stock. Their forecasts range from $5.00 to $20.00. On average, they expect Cytori Therapeutics' stock price to reach $13.8333 in the next twelve months. This suggests a possible upside of 3,358.3% from the stock's current price. View Analyst Price Targets for Cytori Therapeutics.
What is the consensus analysts' recommendation for Cytori Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytori Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytori Therapeutics.
What are Wall Street analysts saying about Cytori Therapeutics stock?
Here are some recent quotes from research analysts about Cytori Therapeutics stock:
- 1. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (10/16/2018)
- 2. HC Wainwright analysts commented, "Our valuation for Cytori is based on success with the current therapeutics pipeline with probability of success factors weighted in each therapeutic area. These forecasts feed into our valuation metrics, of free cash flow to the firm (FCFF), discounted EPS (dEPS) and sum- of-the-parts (SOP) models." (9/18/2018)
- 3. Maxim Group analysts commented, "We are downgrading CYTX shares to and removing our price target (prior $3). Our fundamental view around the company’s key programs of 0918 (liposomal doxorubicin) and cell therapy (scleroderma, stress urinary incontinence) are unchanged, but capital constraints remain, and are an increasing concern." (8/15/2018)
Are investors shorting Cytori Therapeutics?
Cytori Therapeutics saw a drop in short interest in the month of September. As of September 28th, there was short interest totalling 607,828 shares, a drop of 37.0% from the September 14th total of 964,077 shares. Based on an average daily trading volume, of 578,386 shares, the days-to-cover ratio is currently 1.1 days. Currently, 5.7% of the shares of the company are sold short. View Cytori Therapeutics' Current Options Chain.
Who are some of Cytori Therapeutics' key competitors?
Some companies that are related to Cytori Therapeutics include Avinger (AVGR), Alliqua Biomedical (ALQA), Neurometrix (NURO), Atossa Genetics (ATOS), Viatar CTC Solutions (VRTT), United American Healthcare (UAHC), Regenicin (RGIN), Encision (ECIA), Amedica (AMDA), Delcath Systems (DCTH), Calmare Therapeutics (CTTC), Delcath Systems (DCTHD), AdvanSource Biomaterials Corpration (ASNB), OxySure Therapeutics (OXYS) and TearLab (TEAR).
Who are Cytori Therapeutics' key executives?
Cytori Therapeutics' management team includes the folowing people:
- Dr. Marc H. Hedrick, CEO, Pres & Director (Age 55)
- Mr. Tiago M. Girão, VP of Fin., CFO & Sec. (Age 39)
- Dr. John K. Fraser Ph.D., Chief Scientist (Age 57)
- Mr. Russ Havranek, VP of Global Marketing
- Mr. John B. Ferris, Sr. Director of European Bus. Devel. Technology
How do I buy shares of Cytori Therapeutics?
Shares of CYTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytori Therapeutics' stock price today?
One share of CYTX stock can currently be purchased for approximately $0.40.
How big of a company is Cytori Therapeutics?
Cytori Therapeutics has a market capitalization of $3.26 million and generates $2.69 million in revenue each year. The biotechnology company earns $-22,680,000.00 in net income (profit) each year or ($6.50) on an earnings per share basis. Cytori Therapeutics employs 37 workers across the globe.
What is Cytori Therapeutics' official website?
How can I contact Cytori Therapeutics?
Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected]
MarketBeat Community Rating for Cytori Therapeutics (NASDAQ CYTX)
MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe CYTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
